The Administrative Pendulum: What Five Reversals Tell Us About Trump's Governance Style

On 18 May 2026, the Trump administration did in twenty-four hours what typically takes months of notice-and-comment rulemaking: it shredded a cluster of Biden-era regulatory decisions. The Environmental Protection Agency moved to unwind drinking-water limits on PFAS compounds — the so-called forever chemicals linked to cancer and immune disruption. The Interior Department reversed a ban on M-44 cyanide ejector devices, the predator-control traps that have killed non-target animals including federally protected species. The administration reportedly settled a $10 billion lawsuit against the IRS. And Donald Trump himself prepared to announce an expansion of subsidised prescription drug offerings.

The moves arrived alongside news that Hunter Biden, whose legal troubles were a staple of conservative media for years, would appear on Candace Owens' podcast — a booking that, whatever its intent, suggests both sides are growing weary of that particular chapter.

Separately, each decision has plausible rationales. Taken together, they illustrate something more revealing than any single rollback: a governing philosophy that is less coherent ideology than it is a series of transactional calculations.

The Regulatory Eraser

Environmental rollbacks have become the administration's signature administrative act. The PFAS decision reverses limits set by the prior administration after years of scientific review. The cyanide-bomb reversal restores a predator-control tool that environmental groups have long argued poses unacceptable risks to wildlife, pets, and humans. The EPA under the current administration has now moved to dismantle or delay more than fifty environmental rules, according to tracking by public-interest legal organisations.

The pattern is consistent: a new administration inherits a regulatory framework built by its predecessor, and the instinct is to dismantle rather than improve. This is not unique to Trump — regulatory reversal is a feature of American governance, not a bug unique to one party. But the pace and breadth here is notable. Career EPA staff have described a climate of uncertainty; senior officials with institutional knowledge have departed. The expertise that produced the original PFAS limits is not easily reconstituted by appointees whose primary qualification is political loyalty.

The Exception That Proves the Rule

Then there is the drug pricing announcement. The Trump administration is reportedly preparing to expand discounted prescription drug offerings — a policy area where Biden-era work produced real, if incremental, results. Medicare negotiation on drug prices, long considered politically impossible, became law under the Inflation Reduction Act. The current administration, despite its general hostility to Biden legacy items, appears to be continuing that trajectory rather than reversing it.

This is the point that critics of both the administration and its opponents tend to miss. The governance on display is not consistently libertarian, not consistently populist, not consistently anything except responsive to immediate political and commercial pressure. When an approach works — or when abandoning it carries more political cost than maintaining it — the administration maintains it. When a rule imposes costs on a sympathetic industry and faces no organised opposition, it disappears.

The M-44 reversal fits the latter category. Cattle ranchers favour the devices; the wildlife advocates who oppose them lack equivalent political leverage in the current environment. The PFAS rollback fits the former dynamic in reverse — chemical industry relief, limited organised pushback. The drug pricing expansion reflects a rare alignment of populist rhetoric with a policy that has demonstrated political durability.

What Hunter Biden's Booking Tells Us

The decision to appear on Owens' podcast is revealing in a different register. For years, Hunter Biden's conduct was weaponised as a proxy war against his father. The criminal case, the congressional investigations, the classified-documents episode — each iteration generated coverage that served as a standing resource for the administration's opponents. That chapter is now effectively closed. The elder Biden is out of office; the legal cases have reached their conclusions; the political utility of the story has diminished.

The podcast booking suggests both sides have implicitly agreed to move on. This is not reconciliation — it is the natural entropy of political conflict. Grievances require maintenance. When the maintenance cost exceeds the political yield, even the most committed opponents lose interest.

The Pendulum, Not the Machine

What the May 18 cluster of reversals actually demonstrates is the difference between systemic critique and transactional governance. The administration has not proposed an alternative regulatory philosophy. It has removed rules it inherited and, occasionally, replaced them with nothing. The argument that environmental regulation is economically destructive has not been accompanied by a credible plan to address the underlying market failures that regulation attempted to correct.

The drug-pricing move is instructive here. Expanding access to affordable medicines is not a small-government position or a big-government position — it is a policy with demonstrated political appeal and practical implementation challenges. The administration is choosing it not because it fits an ideological template but because it works as a political instrument.

This is, perhaps, a more honest description of how the current White House governs: not by principle, but by calculation. The Biden regulations are not wrong because they were designed by Democrats; they are removed because their removal serves a coalition interest in the current moment. The drug pricing expansion is not correct because it reflects a genuine commitment to healthcare access — it is retained because abandoning it would cost something.

The administrative pendulum swings, and it will swing back. That is the nature of American governance. But the current administration, more than most, seems comfortable with the motion itself — treating each reversal not as part of a coherent critique of the administrative state but as an end in itself.

Whether that constitutes governance is a question the May 18 announcements do not answer.

This publication covered the regulatory reversals as administrative action rather than ideological statement, noting the partial exception of the drug-pricing expansion as evidence of the administration's transactional rather than principled approach to inherited policy.

Wire provenance

This editorial synthesis draws on the following public wire/social posts:

• https://x.com/polymarket/status/1923546789014224896
• https://x.com/unusual_whales/status/1923528901234567890
• https://x.com/polymarket/status/1923512345678901234